Enkaid Related Published Studies
Well-designed clinical trials related to Enkaid (Encainide)
Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I. [1995.12]
Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). [1994.12]
Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST). [1994.02]
Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). [1993.11.24]
Impact of food on the bioavailability of encainide. [1992.09]
Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. [1991.12.15]
Intravenous 3-methoxy-O-desmethyl-encainide in reentrant supraventricular tachycardia: a randomized double-blind placebo-controlled trial in patients undergoing EP study. [1991.09]
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. [1991.03.21]
Encainide--an updated safety profile. [1990.06]
Encainide and flecainide: are they interchangeable? [1989.06]
Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. [1989.04]
Comparison of twice daily with thrice daily administered encainide for benign or potentially lethal ventricular arrhythmias. [1989.01.01]
Comparison of encainide and quinidine for supraventricular tachyarrhythmias. [1988.12.20]
Well-designed clinical trials possibly related to Enkaid (Encainide)
Adherence and arrhythmic mortality in the cardiac arrhythmia suppression trial (CAST). [1996.03]
The Cardiac Arrhythmia Suppression Trial: Implications for nursing practice. [1996.01]
Time to arrhythmic, ischemic, and heart failure events: exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial. [1995.07]
Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial. [1995.05]
Association between ease of suppression of ventricular arrhythmia and survival. [1995.01.01]
Predicting mortality after myocardial infarction from the response of RR variability to antiarrhythmic drug therapy. [1994.03.01]
Psychosocial predictors of mortality in the Cardiac Arrhythmia Suppression Trial-1 (CAST-1). [1993.02.01]
Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST Investigators. [1992.07]
The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II. [1992.04]
Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients. [1991.11.15]
Prevalence, characteristics and significance of ventricular premature complexes and ventricular tachycardia detected by 24-hour continuous electrocardiographic recording in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. [1991.10.01]
Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled. [1991.07]
Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in patients surviving open label titration but not randomized to double-blind therapy. [1991.07]
Clinical aspects of trial design: what can we expect from the cardiac arrhythmia suppression trial? [1990.06]
Recasting the approach to the treatment of potentially malignant ventricular arrhythmias after the CAST study. [1990.06]
Comparisons of efficacy and tolerance of moricizine with other antiarrhythmic agents in the treatment of chronic ventricular arrhythmias. [1990.02.20]
Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment. [1990.02.20]
The Cardiac Arrhythmia Suppression Trial: background, interim results and implications. [1990.01.16]
Relation of baseline characteristics to suppression of ventricular arrhythmias during placebo and active antiarrhythmic therapy in patients after myocardial infarction. [1989.03]
Congestive heart failure after acute myocardial infarction in patients receiving antiarrhythmic agents for ventricular premature complexes (Cardiac Arrhythmia Pilot Study). [1989.02.15]
Other research related to Enkaid (Encainide)
Impact of the Food and Drug Administration approval of flecainide and encainide on coronary artery disease mortality: putting "Deadly Medicine" to the test. [1997.01.01]
Demonstration of proarrhythmic activity with the class IC antiarrhythmic agent encainide in a canine model of previous myocardial infarction. [1993.03]
Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans. [1992.11]
Encainide overdose in an infant. [1992.08]
Encainide-induced diabetes: analysis of islet cell function. [1992.06]
Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: a comparative study with sotalol and encainide. [1992.02]
Encainide dosing in patients with severe renal dysfunction: report of a case and literature review. [1992.01]
Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group. [1991.08]
Pharmacokinetics of encainide in patients with cirrhosis. [1991.08]
Use-dependent actions and effects on transmembrane action potentials of flecainide, encainide, and ethmozine in canine Purkinje fibers. [1991.08]
Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. [1991.05.01]
Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation. [1990.11.01]
Other possibly related research studies
Proarrhythmia of a class Ic drug: suppression by combination with a drug prolonging repolarization in the dog late after infarction. [1995.07]
Antifibrillary action of class I-IV antiarrhythmic agents in the model of ventricular fibrillation threshold of anesthetized guinea pigs. [1995.07]
Efficacy of type 1C antiarrhythmic agents for treatment of resistant atrial fibrillation. [1993.12]
Efficacy of class 1C antiarrhythmic agents in patients with inducible ventricular tachycardia refractory to therapy with class 1A antiarrhythmic drugs. [1993.07]
Efficacy and safety of combination therapy with amiodarone and type I agents for treatment of inducible ventricular tachycardia. [1993.04]
Classifying antiarrhythmic actions: by facts or speculation. [1992.11]
Suppression of longitudinal versus transverse conduction by sodium channel block. Effects of sodium bolus. [1992.06]
Treatment of ventricular arrhythmias after CAST. [1992.04.06]
[Combination anti-arrhythmic drug therapy] [1992]
[What is the latest in anti-arrhythmia therapy?] [1991.11.23]
A prospective comparison of class IA, B, and C antiarrhythmic agents in combination with amiodarone in patients with inducible, sustained ventricular tachycardia. [1991.07]
Significance of classifying antiarrhythmic actions since the cardiac arrhythmia suppression trial. [1991.02]
A critical appraisal of the cardiac arrhythmia suppression trial (CAST). [1991]
Reassessment of benefit-risk ratio and treatment algorithms for antiarrhythmic drug therapy after the cardiac arrhythmia suppression trial. [1990.11]
Effects of cardioactive medications on retrograde conduction: continuing relevance for current devices. [2006.01]
|
